Search

Your search keyword '"Kramm, Christof"' showing total 698 results

Search Constraints

Start Over You searched for: Author "Kramm, Christof" Remove constraint Author: "Kramm, Christof"
698 results on '"Kramm, Christof"'

Search Results

2. Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

3. General support of physical exercise programs in pediatric oncology but differences in perception by childhood cancer care professionals at European and North-African/Arab centers

5. Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

6. Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

8. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.

9. Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

12. Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM

13. Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival

14. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

15. DNA methylation-based classification of central nervous system tumours.

16. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

17. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations

18. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

19. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis

20. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.

21. European Cancer Organisation Essential Requirements for Quality Cancer Care: Adult glioma

22. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B

25. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma

26. Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol.

27. Characterization of an Additional Splice Acceptor Site Introduced into CYP4B1 in Hominoidae during Evolution.

29. DDDR-17. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS

30. Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

31. High-grade Glioma

32. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?

33. HGG-19. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS

35. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group

38. Optimizing the structure of interdisciplinary tumor boards for effective cancer care

39. Abstract 5719: Clinical response to the PDGFRα inhibitor avapritinib in high-grade glioma patients

40. Abstract 3562: Dissecting mechanisms underlying FOXR2-mediated gliomagenesis in diffuse midline gliomas

41. Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

42. Supplementary Table from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

43. Supplementary Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

44. Supplementary Table S3 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

45. Data from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

46. Supplementary Figure from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

47. Supplementary Table from FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits

48. Supplementary Figure from FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits

49. Data from FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits

50. Antimicrobial use in pediatric oncology and hematology in Germany and Austria, 2020/2021: a cross-sectional, multi-center point-prevalence study with a multi-step qualitative adjudication process

Catalog

Books, media, physical & digital resources